Laikai Pharmaceutical-B (02105) rose more than 8%. As of press release, it was up 7.3% to HK$5.73, with a turnover of HK$206.395 million.
The Zhitong Finance App learned that Lai Kai Pharmaceutical-B (02105) rose more than 8%. As of press release, it had risen 7.3% to HK$5.73, with a turnover of HK$206.395 million.
According to the news, Laikai Pharmaceutical recently announced that its self-developed LAE102 (ActRIa monoclonal Antibody) has been approved by the US Food and Drug Administration (FDA) for new drug clinical trials (IND) to treat obese patients. Huachuang Securities previously pointed out that the world's first Actriia monoclonal antibody LAE102 can gain muscle and lose fat. It has potential to be used in combination with GLP-1RA, and has huge market potential and international value.
Pacific Securities, on the other hand, indicated that the company's core pipeline in 2024 had multiple catalysts. 1) LAE102 IND Program 24H2 for Obesity Indications launches the first human clinical study. 2) Phase 2b data of bimagrumab is expected to be read in 24H2; 3) LAE002 combined with fluvirizil for breast cancer initiates patient recruitment in 2024H2; 4) LAE002 combined with fluvirizil for breast cancer phase 1b clinical data and biomarker data are expected to be presented at the 24H2 academic conference.